SCTA01

BIOLOGICAL4 trials

Sponsors

Sinocelltech Ltd.

Conditions

COVID-19Coronavirus Disease 2019(COVID-19)Covid19SARS-CoV-2

Phase 1

Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects

CompletedNCT04483375

Sinocelltech Ltd.Coronavirus Disease 2019(COVID-19)

Start: 2020-07-24End: 2020-11-17Updated: 2021-03-23

Phase 2

The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

TerminatedNCT04644185

Sinocelltech Ltd.Covid19

Start: 2021-03-27End: 2022-02-11Updated: 2025-10-24

The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care

Sinocelltech Ltd.Covid19

Start: 2021-02-25End: 2021-11-25Target: 560Updated: 2021-01-20

To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19

Not yet recruitingNCT04709328

Sinocelltech Ltd.COVID-19, SARS-CoV-2

Start: 2021-03-28End: 2022-03-01Target: 690Updated: 2021-03-29

Related Papers

Efficacy and safety of SARS-CoV-2 neutralizing antibody, SCTA01, in high-risk outpatients diagnosed with COVID-19: A Phase II clinical trial.

2025-05-17

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study.

2021-09-0712 citations